Related Experiment Video
Updated: Jun 30, 2026
10:19
Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Published on: November 10, 2014
25.5K
Castleman disease coexisting with papillary thyroid carcinoma: A case report
Fei Wu1, Honghao Li1, Rui Hai1
1Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Oncology Letters
|March 17, 2025
Summary
Castleman disease (CD), a rare lymphoproliferative disorder, is often misdiagnosed. This case highlights the importance of considering CD alongside papillary thyroid carcinoma (PTC) to avoid diagnostic errors.
Area of Science:
- Oncology
- Pathology
Background:
- Castleman disease (CD) is a rare lymphoproliferative disorder often presenting with lymph node enlargement.
- Diagnosis of CD is challenging due to non-specific symptoms and reliance on histopathology.
- CD is frequently misdiagnosed as lymphoma or autoimmune conditions.
Observation:
- A rare co-occurrence of papillary thyroid carcinoma (PTC) and CD in a patient is presented.
- The patient presented with a thyroid nodule and a supraclavicular fossa mass.
- Postoperative histopathology confirmed PTC with lymph node metastasis and CD in the supraclavicular fossa.
Findings:
- Immunohistochemistry differentiated between PTC metastasis and CD.
- Specific markers like thyroglobulin and thyroid transcription factor-1 confirmed PTC.
- CD markers (Bcl-2, Bcl-6, CD38) were evaluated in the supraclavicular mass.
Implications:
- Clinicians should consider CD as a differential diagnosis in PTC patients with mediastinal masses.
- Accurate diagnosis requires careful pathological examination to distinguish CD from metastasis.
- This case provides insights for managing coexisting PTC and CD.
